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Abstract
Introduction: Antiretrovirals such as dolutegravir (DTG) and tenofovir alafenamide (TAF) have been associated with excessive
weight gain. The objective of this study was to understand the potential impact of ART-associated weight gain on pregnancy
outcomes among women living with HIV.
Methods: Using data from the Tsepamo birth outcomes surveillance study in Botswana, we evaluated the relationship
between maternal weight (and weight gain) and severe birth outcomes (very preterm delivery <32 weeks, very small for gesta-
tional age (SGA) <3rd percentile, perinatal death), macrosomia (birthweight > 4000 g) and maternal hypertension. We esti-
mated the relative risk of each outcome by baseline weight (first weight in pregnancy <24 weeks) and second trimester
average weekly weight gain (kg/week from 12  2 to 24  2 weeks) using log binomial regression and evaluated effect modi-
fication by ART regimen (DTG vs. Efavirenz (EFV)).
Results: Of 22,828 women on ART at conception with singleton deliveries between August 2014 and April 2020, 16,300
(71.4%) had a weight measured <24 weeks’ gestation (baseline weight) and 4437 (19.2%) had weight measured both at 12
(2) weeks and 24 (2) weeks, allowing second trimester weight gain calculation. Compared to women with baseline weight
60 to 70 kg, low baseline weight (<50 kg) was associated with increased risk of very preterm delivery (aRR 1.30, 95% CI
1.03, 1.65) and very SGA (aRR1.96, 95% CI 1.69, 2.28). High baseline weight (>90 kg) was associated with increased risk of
macrosomia (aRR 3.24, 95% CI 2.36, 4.44) and maternal hypertension (aRR 1.79, 95% CI 1.62, 1.97). Baseline weight was not
associated with stillbirth or early neonatal death. For all outcomes, second trimester weight gain showed weaker associations
than did baseline weight. Duration of pre-pregnancy ART (years) was associated with higher baseline weight for DTG but not
for EFV, and the risk of maternal hypertension by baseline weight category was higher for DTG than EFV for all strata.
Conclusions: ART regimens associated with weight gain may reduce the number of women at risk for certain severe adverse
pregnancy outcomes associated with low weight but increase the number at risk of macrosomia and maternal hypertension.
Further research could determine whether weight-based ART treatment strategies improve maternal and child health.
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1 | INTRODUCTION
Multiple studies have reported that tenofovir alafenamide
(TAF) and dolutegravir (DTG) are associated with clinically sig-
nificant weight gain, with risk of treatment-emergent obesity
(body mass index, or BMI, >30) more than three times higher
after 96 weeks among women randomized to TAF/emtric-
itabine (FTC)/DTG compared with tenofovir disoproxil fuma-
rate (TDF)/FTC/efavirenz (EFV) in the ADVANCE trial [1,2].
Female gender has consistently been an independent predic-
tor of excess weight gain on integrase inhibitor-based
antiretroviral treatment (ART) in both low-resource [1,2] and
high-resource [3-5] settings. In pregnancy, excess weight leads
to maternal complications during labour, and adverse foetal
outcomes due to gestational diabetes, hypertension and infant
macrosomia. Thus, ART-associated excess weight gain has the
potential to substantially worsen maternal and infant health
outcomes [6-9].
However, it is also possible that increases in weight may
provide benefits to pregnant women with HIV. Women on
ART are known to be at increased risk of adverse birth out-
comes, including preterm delivery and delivering infants who
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are small for gestational age (SGA), which may be related to
low maternal weight and low gestational weight gain (GWG)
[10-19]. A recent study found that women starting DTG-
based ART gained significantly more weight in pregnancy than
women starting EFV-based ART, but both gained less than
demographically similar women without HIV [20]. Additionally,
the VESTED trial, found those randomized to start TAF/FTC/
DTG in pregnancy had more GWG, but 8% fewer adverse
birth outcomes, compared to women randomized to TDF/
FTC/EFV [21].
Determining how ART-associated weight gain will impact
outcomes is challenging because most data on weight and
pregnancy outcomes comes from resource-rich settings with
low HIV prevalence [22-24] or from lower resourced settings
before ART was available [25,26]. In the pre-ART era, wasting
and malnutrition associated with AIDS led to adverse preg-
nancy outcomes such as foetal growth restriction and foetal
death [25,26]. However, little is known about the effect of
weight in pregnant women on ART, particularly those starting
ART prior to conception with high CD4 count and viral sup-
pression, who now represent the majority of pregnant women
living with HIV (WLWHIV) [27]. Also, pre-pregnancy weight
may impact pregnancy outcomes more than GWG [23,24], so
ART-associated weight gain is likely to have the greatest
impact among women on ART prior to pregnancy.
To better understand how ART-associated increases in
weight over time will impact pregnancy we first need data on
the impact of maternal weight on pregnancy outcomes among
WLWHIV. We utilized the Tsepamo study in Botswana to
define the existing associations between baseline weight and
weight gain on pregnancy outcomes among women receiving
ART from conception. We also evaluated differences in these
associations by ART regimen (TDF/XTC/DTG or TDF/XTC/
EFV, where XTC indicates either emtricitabine [FTC] or lami-
vudine [3TC]).
2 | METHODS
2.1 | Study population and setting
This analysis included women documented to be on ART at
conception with singleton pregnancies who delivered 15
August 2014 to 30 April 2020 in the Tsepamo study in Bots-
wana. All women had to have a weight measurement during
antenatal care before 24 weeks so that the weight measure-
ment occurred before the birth outcomes, which start at
≥24 weeks’ gestational age (GA). Pregnancies ending
<24 weeks are considered miscarriage and are not captured
in Tsepamo. Methodologic details of Tsepamo have been previ-
ously described [10,11]. Briefly, research assistants abstract
data from the obstetric record (a record of antenatal care and
delivery) at the time of delivery from all women delivering at
study sites. From the obstetric record, we recorded maternal
demographics, medical history, medications prescribed during
pregnancy, diagnoses, clinical visits and hospital admissions
during pregnancy, maternal HIV status, dates of HIV diagnosis
and ART initiation and ART treatment regimens. Infant GA,
vital status, birthweight and gender were also recorded for
each delivery. GA was calculated at the time of delivery by
the midwife using the estimated date of delivery determined
during antenatal care, typically using the reported last
menstrual period (LMP). Every maternal weight and blood
pressure measured during an antenatal clinic appointment was
recorded (with the date). Blood pressures were single mea-
surements and measurements during labour in the inpatient
setting were not collected. Pre-pregnancy weight was by
maternal self-report. Data on height were not available, pre-
venting calculation of BMI.
The national HIV treatment programme in Botswana pro-
vides free testing, medical care and ART treatment. During
the study period, TDF/FTC/EFV was the first-line recom-
mended regimen for ART initiation among ART-na€ıve individu-
als until May 2016, when it was replaced by TDF/FTC/DTG,
which was subsequently replaced by TDF/3TC/DTG in
September 2018. Patients stable on previously recommended
regimens were not switched to the newer regimens (with the
exception of the TDF/FTC/DTG formulation being replaced by
TDF/3TC/DTG), so there were many women on ART with
nevirapine (NVP), lopinavir-ritonavir (LPV-r) and EFV who
delivered throughout the study.
2.2 | Exposures
Baseline weight was defined as the initial weight in kilograms
(kgs) measured during pregnancy at <24 weeks’ GA, catego-
rized in 10 kg increments (<50, 50 to 60, 60 to 70, 70 to 80,
80 to 90 and >90 kg). We felt this definition would be more
accurate than using pre-pregnancy weight which was self-
reported, and less biased than restricting to only first trime-
ster measured weight in pregnancy, which was available for a
smaller proportion of women who may have presented to
antenatal care early due to complications/comorbidities. GWG
was defined as the average weekly weight gain in the second
trimester, using the difference in weight at 12  2 and
24  2 weeks, divided by the number of weeks between
measurements (kg/week). Limiting GWG to the second trime-
ster was necessary so that the exposure (weight gain) comes
before the birth outcome (which occurs ≥24 weeks’ GA).
GWG was categorized (<0.15, 0.15 to 0.25, 0.25 to 0.35, 0.35
to 0.45, 0.45 to 0.55 and >0.55 kg/week) based on the distri-
bution of weight gain in the Botswana population, and closely
approximate Institute of Medicine (IOM) recommendations for
inappropriately low (0.18 kg/week) and inappropriate high
(0.59 kg/week) second and third trimester weight gain
(though IOM guidelines are based on pre-pregnancy BMI)
[20,22]. For both baseline weight and second trimester weight
gain, the strata that included the median baseline weight/
weight gain was defined as the referent (moderate) strata.
Weight strata below the referent were considered low base-
line weight/low weight gain while strata above the referent
were considered high baseline weight/high weight gain.
2.3 | Outcomes
Severe birth outcomes considered in our analysis were very
preterm delivery (<32 weeks’ GA), very SGA (<3rd percentile
weight-for-GA per INTERGROWTH-21 norms), or perinatal
death (stillborn or in-hospital neonatal death at <28 days old).
“Any severe birth outcome” refers to a composite endpoint of
very preterm, very SGA and/or perinatal death. Macrosomia
was defined as birthweight >4000 g. The primary definition of
hypertension in pregnancy was any elevated systolic blood
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pressure (SBP) >140 or diastolic blood pressure (DBP) >90
during pregnancy.
2.4 | Covariates
Maternal age, occupation, marital status, education and parity
were self-reported at the first antenatal clinic visit. CD4 count
testing is recommended every 6 to 12 months for people with
stable HIV in Botswana, and was recorded in Tsepamo if
obtained during pregnancy. Duration of ART prior to preg-
nancy was calculated from the start date of ART to the esti-
mated date of conception (<1, 1 to 2, 2 to 3, >3 years). Site
of delivery was defined as tertiary (2 sites) versus non-
tertiary (all other sites).
2.5 | Statistical analysis
For the primary analysis, we described the population distribu-
tion of baseline weight and second trimester weight gain and
calculated the prevalence of each individual outcome by (1)
baseline weight, (2) second trimester weight gain and (3) sec-
ond trimester weight gain stratified by baseline weight. The
association of baseline weight and second trimester weight
gain with each outcome was evaluated separately using
multivariable log binomial regression to estimate relative risk
(RR). Variables considered potential confounders (a-priori)
were evaluated individually, and included in adjusted models if
they changed the effect estimate by >5%. We included evalua-
tion of baseline weight as a potential confounder in the rela-
tionship between second trimester weight gain and outcomes.
However, we hypothesized that second trimester weight gain
was a mediator between baseline weight and outcomes, and
did not adjust for weight gain in models of baseline weight
and outcomes, as we did not want to condition on a mediator.
A secondary analysis was performed to test for interaction
between baseline weight and outcomes by ART regimen.
Given our primary interest in understanding how pregnancy
outcomes may be impacted by the increasing use of DTG
(which is replacing EFV in most HIV treatment programmes
globally) [28,29] we chose to limit this analysis to TDF/XTC/
DTG versus TDF/XTC/EFV. We fit adjusted log binomial mod-
els as described above to evaluate each individual outcome by
baseline weight, and included ART regimen (DTG/EFV) and an
interaction term (for DTG/EFV).
Several sensitivity analyses were also performed, including
(1) defining baseline weight as pre-pregnancy weight, (2)
defining baseline weight as measured weight <14 weeks’ GA
and (3) limiting the analysis to women with a known CD4















Gestational weeks at measured
weight, median [IQR]
15 [12, 18] 16 [12, 19] 16 [13, 20] 16 [12, 19] 16 [12, 19] 16 [12, 19]
Maternal Age, median
[IQR] years
29 [24, 34] 31 [26, 35] 33 [29, 37] 34 [30, 38] 35 [31, 38] 35 [31, 38]
No/primary school education 313 (15%) 590 (13%) 506 (12%) 294 (11%) 169 (11%) 112 (9.8%)
Current student 44 (2.2%) 112 (2.5%) 58 (1.4%) 28 (1.1%) 9 (0.6%) 8 (0.7%)
Unemployed, No. (%) 1359 (68%) 2751 (62%) 2289 (56%) 1339 (51%) 735 (49%) 517 (46%)
Married, No (%) 93 (4.6%) 346 (7.7%) 500 (12%) 465 (18%) 294 (19%) 239 (21%)
Nulliparity, No. (%) 436 (21%) 656 (14%) 377 (8.9%) 121 (4.5%) 63 (4.0%) 37 (3.2%)
≥5 prior pregnancies 338 (16%) 967 (21%) 1055 (25%) 722 (27%) 436 (28%) 355 (31%)
Number of antenatal care visits,
median [IQR]
10 [8, 12] 10 [8, 12] 10 [8, 13] 11 [8, 13] 11 [9, 13] 11 [9, 13]
Delivery at tertiary care
hospital No. (%)
814 (40%) 1857 (41%) 1700 (40%) 1144 (43%) 664 (43%) 530 (46%)
CD4 count, median [IQR] 537.5 [414, 698] 539 [406, 673] 526 [403, 678] 562.5 [423, 721] 573 [437, 729.5] 625 [465.5, 793]
CD4 < 200 cells/mm3 22 (4.0%) 38 (3.3%) 23 (2.2%) 21 (3.0%) 10 (2.5%) 8 (2.4%)
CD4 > 500 cells/mm3 325 (59%) 683 (59%) 589 (55%) 589 (55%) 251 (63%) 232 (71%)
ART regimen contains
DTG 374 (18%) 670 (14%) 590 (14%) 381 (14%) 231 (15%) 204 (18%)
EFV 972 (47%) 2197 (48%) 1906 (45%) 1158 (43%) 708 (46%) 518 (45%)
NVP 677 (33%) 1150 (25%) 1252 (30%) 855 (32%) 452 (29%) 309 (27%)
LPV-r 127 (6.2%) 243 (5.3%) 205 (7.7%) 131 (4.9%) 72 (4.6%) 63 (5.5%)
Other/unknown 141 (6.9%) 289 (6.4%) 246 (5.9%) 141 (5.3%) 88 (5.7%) 51 (4.5%)
ART, antiretroviral treatment; DTG, dolutegravir; EFV, efavirenz; IQR, inter quartile range; KG, kilogram; LPV-r, lopinavir/ritonavir; NVP, nevirapine.
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count. The latter analysis was considered a sensitivity analysis
because less than 30% of the study population had a reported
CD4, and less than 3% of women in our study population had
CD4 count <200, so we expected minimal confounding bias
via increased risk for infections.
2.6 | Ethics
Ethical approval for this study, including waiver of informed
consent, was granted by Human Research and Development
Council in Botswana and by the IRB at the Harvard T.H. Chan
School of Public Health.
3 | RESULTS
A total of 22,828 women on ART at conception delivered a
singleton infant between 15 August 2015 and 30 April 2020,
of whom 21,406 (94%) had a weight measured during preg-
nancy. The analysis of baseline weight includes 16,300 (76%)
who had a weight measurement before 24 weeks’ gestation.
Of these women, 4437 had weight measurements available at
both 12 (2) weeks and 24 (2) weeks and were included in
the analysis of second trimester weight gain. The median base-
line weight was 63.0 kg [interquartile range (IQR) 54.4, 74.0],
13% of women had very low baseline weight (<50 kg) and 7%
had very high baseline weight (>90 kg). The mean second tri-
mester weight gain was 0.33 kg/week, 21% had very low sec-
ond trimester weight gain (<0.15 kg/week) and 15% had very
high second trimester weight gain (>0.55 kg/week). Low base-
line weight was associated with younger age, lower educa-
tional attainment, lack of employment, nulliparity and slightly
lower median CD4 count (Table 1). Low second trimester
weight gain was associated with lower educational attainment,
lack of employment, grand multiparity (>5 prior pregnancies)
and slightly higher median CD4 count (Table 2). Women with
lower baseline weight tended to have moderate to high sec-
ond trimester weight gain while women with higher baseline
weight tended to have lower second trimester weight gain
(Figure 1).
3.1 | Baseline weight and outcomes
Table 3 shows the prevalence of each outcome by baseline
weight category. Very preterm delivery and very SGA
decreased linearly with increasing baseline weight, and both
Table 2. Characteristics of women on ART at conception by average weekly second trimester weight gain (12  2 to 24 2 weeks’
gestational age)














Gestational weeks at measured
weight, median [IQR]
12 [10, 13] 12 [9, 13] 12 [10, 13] 12 [9, 13] 12 [9, 13] 12 [9, 13]
Maternal Age, median [IQR] years 33 [29, 37] 33 [28, 37] 33 [28, 36] 33 [28, 36] 32 [28, 36] 31 [27, 36]
Baseline Weight, median [IQR] kg 71.2 [60.5, 83.4] 66.0 [56.0, 76.0] 60.7 [52.6, 72.0] 59.1 [52., 69.8] 57.8 [51.5, 68.8] 60.2 [52.7, 70.0]
No/primary school education 109 (12%) 68 (10%) 68 (8%) 68 (9%) 55 (9%) 55 (8%)
Current Student 10 (1.1%) 8 (1.2%) 14 (1.7%) 16 (2.1%) 11 (1.9%) 14 (2.2%)
Unemployed, No. (%) 485 (55%) 325 (50%) 409 (51%) 393 (52%) 283 (49%) 304 (48%)
Married, No (%) 117 (13%) 105 (16%) 135 (17%) 103 (14%) 89 (15%) 76 (12%)
Nulliparity, No. (%) 77 (8.5%) 81 (12%) 104 (13%) 105 (14%) 89 (15%) 100 (15%)
≥5 prior pregnancies 196 (22%) 19 (18%) 157 (19%) 135 (17%) 103 (17%) 102 (16%)
Number of antenatal care visits,
median [IQR]
12 [10, 14] 12 [10, 14] 12 [10, 14] 12 [10, 14] 12 [10, 14] 12 [10, 14]
Delivery at tertiary care
hospital No. (%)
356 (39%) 278 (41%) 368 (44%) 347 (45%) 275 (46%) 290 (44%)
CD4 count, median [IQR] 555 [413, 713] 547 [395, 685] 526 [403, 678] 548 [430, 704] 490 [388, 658] 514 [399, 683]
CD4 < 200 cells/mm3 5 (2.0%) 7 (3.9%) 3 (1.4%) 5 (2.3%) 8 (4.9%) 8 (4.4%)
CD4 > 500 cells/mm3 148 (60%) 104 (58%) 133 (62%) 132 (61%) 80 (48%) 97 (53%)
ART regimen contains
DTG 141 (16%) 98 (15%) 131 (16%) 148 (19%) 96 (16%) 107 (16%)
EFV 405 (45%) 325 (49%) 365 (44%) 336 (43%) 252 (42%) 293 (45%)
NVP 243 (27%) 172 (26%) 247 (30%) 211 (27%) 179 (30%) 182 (28%)
LPV-r 44 (4.9%) 40 (6.0%) 42 (5.1%) 33 (4.3%) 34 (5.7%) 29 (4.5%)
Other/unknown 61 (6.8%) 33 (4.9%) 39 (4.7%) 44 (5.7%) 37 (6.2%) 38 (5.9%)
ART, antiretroviral treatment; DTG, dolutegravir; EFV, efavirenz; IQR, inter quartile range; KG, kilogram; LPV-r, lopinavir/ritonavir; NVP, nevirapine.
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were highest among women with baseline weight <50 kg and
lowest among women with baseline weight >90 kg (5.33% vs.
2.94% very preterm and 14.72% vs. 5.75% very SGA). Perina-
tal death prevalence was similar across all baseline weight
strata. The prevalence of macrosomia increased with increas-
ing baseline weight, from 0.19% for baseline weight <50 kg to
6.32% for >90 kg. Maternal hypertension (median onset of
31 weeks’ GA [IQR 22, 36]) had the same pattern, from
Figure 1. Heatmap showing the distribution of baseline pregnancy weight and second trimester weight gain among women on ART at con-
ception in Botswana. Only women with a known baseline weight and a known second trimester weight gain are included (N = 4437). Each cell repre-
sents the number of women within that individual cell. For example, there were 10 women with baseline weight of <50 kg who also had ≤0 kg/week
second trimester weight gain.
Table 3. Prevalence of outcomes by baseline weight measured in pregnancy among women on ART at conception: overall and
stratified by ART regimen (DTG vs. EFV)
Baseline weight (kg)
<50 50 to 60 60 to 70 70 to 80 80 to 90 >90
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Any severe adverse outcome
Total population 425 (20.6%) 673 (14.7%) 581 (13.7%) 304 (11.3%) 164 (10.5%) 115 (10.0%)
DTG/TDF/XTC 57 (17.8%) 58 (9.8%) 52 (9.96%) 30 (8.6%) 20 (9.8%) 17 (9.3%)
EFV/TDF/XTC 165 (18.1%) 256 (12.2%) 226 (12.3%) 108 (9.5%) 57 (8.3%) 38 (4.5%)
Very preterm delivery
Total population 110 (5.3%) 210 (4.6%) 193 (4.6%) 98 (3.6%) 49 (3.1%) 34 (2.9%)
DTG/TDF/XTC 14 (4.4%) 23 (3.9%) 18 (3.5%) 10 (2.9%) 5 (2.4%) 4 (2.2%)
EFV/TDF/XTC 44 (4.8%) 87 (4.2%) 73 (4.0%) 37 (3.3%) 17 (2.5%) 13 (2.6%)
Very small for gestational age
Total population 301 (14.7%) 436 (9.6%) 342 (8.1%) 167 (6.3%) 99 (6.4%) 66 (5.8%)
DTG/TDF/XTC 43 (13.5%) 32 (5.5%) 34 (6.6%) 17 (4.9%) 10 (5.0%) 11 (6.1%)
EFV/TDF/XTC 113 (12.5%) 161 (7.7%) 135 (7.4%) 58 (5.2%) 40 (5.9%) 22 (4.4%)
Perinatal death
Total population 99 (4.8%) 176 (3.8%) 189 (4.5%) 118 (4.4%) 60 (3.9%) 54 (4.7%)
DTG/TDF/XTC 11 (3.4%) 14 (2.4%) 18 (3.5%) 13 (3.7%) 9 (4.4%) 10 (5.5%)
EFV/TDF/XTC 33 (3.6%) 62 (3.0%) 68 (3.7%) 36 (3.2%) 17 (2.5%) 17 (3.4%)
Macrosomia
Total population 4 (0.2%) 40 (0.9%) 83 (2.0%) 73 (2.7%) 58 (3.7%) 73 (6.3%)
DTG/TDF/XTC 1 (0.3%) 9 (1.5%) 14 (2.7%) 14 (4.0%) 10 (4.9%) 11 (6.0%)
EFV/TDF/XTC 2 (0.2%) 27 (1.3%) 39 (2.1%) 36 (3.2%) 29 (4.2%) 32 (6.4%)
Maternal hypertension
Total population 227 (11.0%) 606 (13.2%) 814 (19.2%) 648 (24.1%) 472 (30.3%) 425 (36.8%)
DTG/TDF/XTC 35 (10.9%) 78 (13.2%) 101 (19.4%) 92 (26.4%) 70 (34.2%) 70 (38.5%)
EFV/TDF/XTC 73 (8.0%) 209 (10.0%) 262 (14.2%) 205 (18.1%) 174 (25.3%) 162 (32.2%)
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11.02% for baseline weight <50 kg to 36.83% for baseline
weight >90 kg.
In adjusted analysis (Figure 2), compared to women with
moderate baseline weight (60 to 70 kg), there was an
increased risk of “any severe adverse birth outcome” and very
SGA in those with lower baseline weight (<50 and 50 to
60 kg) and increased risk of very preterm delivery when base-
line maternal weight was <50 kg. In contrast, there was a
decreased risk of “any severe adverse birth outcome,” very
SGA and very preterm delivery in women with higher baseline
weight (70 to 80, 80 to 90 and >90 kg) compared with mod-
erate baseline weight (60 to 70 kg). For the outcome of
macrosomia and maternal hypertension women with low base-
line weight (<50 and 50 to 60 kg) were at lower risk than
women of moderate baseline weight (60 to 70 kg) while
women with high baseline weight (70 to 80, 80 to 90,
>90 kg) were at higher risk.
Sensitivity analyses using pre-pregnancy weight and mea-
sured weight <14 weeks’ GA to define baseline weight yielded
similar results (Table 4). Among 4218 (25.9%) of women with
documented CD4 count in pregnancy, the risk of severe
adverse outcomes was higher in women with CD4 > 500 than
CD4 < 500 cells/mm3 when baseline weight was >70 kg, but
lower if baseline weight was 60 kg or less, whereas macroso-
mia and maternal hypertension were similar across baseline
weight groups when stratified by CD4 (Table 5) and there
was no significant interaction by CD4 count for any of the
outcomes.
3.2 | Second trimester weight gain and outcomes
Overall, average second trimester weight gain had a smaller
effect on outcomes than baseline weight (Figure 3), and asso-
ciations did not change substantially when additionally control-
ling for baseline weight (Table 6). Compared to moderate
weight gain (0.25 to 0.35 kg/week), the prevalence of very
SGA was higher and the prevalence of very preterm, perinatal
death and macrosomia was in the lowest weight gain category
Figure 2. Risk of outcomes by baseline weight in pregnancy (<24 weeks GA) among women on ART at conception.
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(<0.15 kg/week), but these differences were not significant in
adjusted analyses. Macrosomia, very preterm delivery and
perinatal death were highest in women who gained the most
weight (>0.55 kg/week), though the only significant difference
in the adjusted analysis was increased risk of macrosomia
(aRR 2.01, 95% CI 1.08, 3.74) when compared to 0.25 to
0.35 kg/week.
Figure 4 shows the prevalence of each outcome by cate-
gories of second trimester weight gain, stratified by categories
of baseline weight. The highest prevalence of severe birth out-
comes occurred among the women with the lowest baseline
weight, regardless of second trimester weight gain, though
there was also increased prevalence among women with high
second trimester weight gain (>0.55 kg/week), regardless of
baseline weight (Figure 4A). Macrosomia prevalence was high-
est among women of higher baseline weight with higher sec-
ond trimester weight gain, and lowest among women with low
baseline weight, particularly with lower second trimester
weight gain (Figure 4B). Maternal hypertension was highest
among women of higher baseline weight across strata of
weight gain, except for a modest decrease in those with very
low second trimester weight gain (Figure 4C).
3.3 | Baseline weight and outcomes stratified by
ART regimen
Compared with women on DTG, women on EFV were older
on average, less often primigravid, and had been on ART for a
longer duration prior to pregnancy (198 vs. 65 weeks), but
had a similar median baseline weight (62.5 vs. 62.9 kg).
Slightly more women on DTG than EFV had baseline weight
<50 kg (14.8% vs. 12.7%) or >90 kg (8.4% vs. 7.0%). When
restricting only to those who started ART in the time period
when DTG was available (since May 2016), baseline weight
was still similar (62.9 kg for DTG vs. 62.3 kg for EFV), but
second trimester weight gain was greater with DTG than with
Table 4. Sensitivity analysis for prevalence and adjusted relative risk (aRR) of outcomes by pre-pregnancy weight and by baseline
weight at <14 weeks’ GA among women on ART at conception
Maternal weight
<50 kg 50 to 60 kg 60 to 70 kg 70 to 80 kg 80 to 90 kg >90 kg
Any severe adverse outcome
Pre-pregnancy weight 242 (18.5%) 324 (13.1%) 233 (13.2%) 123 (11.4%) 60 (10.2%) 33 (7.3%)
aRR (95% CI) 1.51 (1.27, 1.79) 0.99 (0.85, 1.17) REF 0.85 (0.69, 1.04) 0.76 (0.58, 1.00) 0.53 (0.37, 0.76)
Baseline Wt < 14 weeks’ GA 210 (20.2%) 272 (13.4%) 206 (11.8%) 126 (10.8%) 69 (10.3%) 40 (7.7%)
aRR (95% CI) 1.86 (1.55, 2.24) 1.20 (1.01, 1.43) REF 0.88 (0.71, 1.09) 0.86 (0.66, 1.11) 0.64 (0.46, 0.89)
Very preterm delivery
Pre-pregnancy weight 65 (5.0%) 109 (4.4%) 64 (3.6%) 34 (3.2%) 20 (3.4%) 13 (2.9%)
aRR (95% CI) 1.48 (1.04, 2.09) 1.19 (0.87, 1.62) REF 0.86 (0.57, 1.30) 0.92 (0.56, 1.52) 0.79 (0.44, 1.43)
Baseline Wt < 14 weeks’ GA 55 (5.3%) 87 (4.3%) 67 (3.8%) 41 (3.5%) 17 (2.5%) 8 (1.6%)
aRR (95% CI) 1.51 (1.05, 2.17) 1.20 (0.87, 1.65) REF 0.86 (0.59, 1.28) 0.58 (0.33, 1.01) 0.35 (0.16, 0.76)
Very small for gestational age
Pre-pregnancy weight 166 (12.8%) 202 (8.2%) 134 (7.7%) 75 (7.0%) 34 (5.8%) 15 (3.4%)
aRR (95% CI) 1.81 (1.45, 2.26) 1.08 (0.98, 1.34) REF 0.90 (0.69, 1.19) 0.75 (0.52, 1.08) 0.41 (0.24, 0.70)
Baseline Wt < 14 weeks’ GA 148 (14.3%) 177 (8.8%) 117 (6.8%) 72 (6.2%) 43 (6.5%) 26 (5.1%)
aRR (95% CI) 2.34 (1.84, 2.97) 1.37 (1.09, 1.73) REF 0.92 (0.69, 1.23) 0.95 (0.67, 1.34) 0.76 (0.50, 1.15)
Perinatal death
Pre-pregnancy weight 55 (4.2%) 92 (3.7%) 84 (4.8%) 39 (3.6%) 23 (3.9%) 18 (4.0%)
aRR (95% CI) 1.00 (0.71, 1.41) 0.80 (0.59, 1.07) REF 0.73 (0.50, 1.07) 0.80 (0.51, 1.26) 0.82 (0.50, 1.36)
Baseline Wt < 14 weeks’ GA 51 (4.9%) 76 (3.7%) 80 (4.6%) 52 (4.4%) 25 (3.7%) 16 (3.1%)
aRR (95% CI) 1.20 (0.84, 1.72) 0.89 (0.65, 1.22) REF 0.93 (0.65, 1.32) 0.76 (0.48, 1.21) 0.64 (0.37, 1.10)
Macrosomia
Pre-pregnancy Weight 11 (0.8%) 32 (1.3%) 35 (2.0%) 35 (3.3%) 17 (2.9%) 36 (8.0%)
aRR (95% CI) 0.43 (0.22, 0.85) 0.66 (0.41, 1.06) REF 1.70 (1.07, 2.71) 1.50 (0.84, 2.67) 4.11 (2.58, 6.53)
Baseline Wt < 14 weeks’ GA 3 (0.3%) 20 (1.0%) 36 (2.1%) 42 (3.6%) 31 (4.6%) 29 (5.6%)
aRR (95% CI) 0.15 (0.05, 0.50) 0.51 (0.30, 0.89) REF 1.79 (1.14, 2.80) 2.27 (1.40, 3.69) 2.75 (1.68, 4.50)
Maternal hypertension
Pre-pregnancy weight 124 (9.6%) 394 (16.0%) 326 (18.6%) 297 (27.7%) 179 (30.3%) 159 (35.2%)
aRR (95% CI) 0.58 (0.48, 0.71) 0.89 (0.78, 1.02) REF 1.45 (1.26, 1.67) 1.56 (1.34, 1.83) 1.73 (1.47, 2.03)
Baseline Wt < 14 weeks’ GA 120 (11.6%) 294 (14.5%) 358 (20.6%) 312 (26.6%) 220 (32.8%) 208 (40.2%)
aRR (95% CI) 0.60 (0.49, 0.73) 0.74 (0.64, 0.85) REF 1.24 (1.09, 1.42) 1.56 (1.35, 1.80) 1.88 (1.6, 2.2)
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EFV (0.33 vs. 0.27 kg/week). Although median baseline weight
did not differ by length of time on ART prior to conception
for EFV (62.0 kg <1 year, 61.5 kg 1 to 2 years, 62.0 kg 2 to
3 years; p = 0.37), it increased with ART duration for DTG
(62.5 kg <1 year, 63.3 kg 1 to 2 years, 64.4 kg 2 to 3 years;
p = 0.11).
The prevalence of any severe adverse birth outcome, very
SGA and perinatal death was all higher in women with very
high baseline weight (>90 kg) who were on DTG rather than
EFV but these same outcomes were less common in women
on DTG with baseline weight 50 to 60 and 60 to 70 kg
(Table 3). However, ART regimen was not a significant effect
modifier for these outcomes in adjusted analyses. The preva-
lence of maternal hypertension was higher among women on
DTG compared with EFV across all baseline weight strata, and
in adjusted analyses, ART regimen was a significant effect
modifier (p < 0.001) for the relationship between baseline
weight and this outcome.
4 | DISCUSSION
We utilized a large birth outcomes surveillance study in Bots-
wana to conduct the largest study, to our knowledge, to evalu-
ate the relationship between weight in pregnancy and
pregnancy outcomes among women living with HIV on ART at
conception, and the first in the DTG era. We found that base-
line pregnancy weight had a greater impact on adverse preg-
nancy outcomes than second trimester weight gain. Low
baseline weight increased the risk for severe birth outcomes
(particularly very preterm and very SGA), whereas high base-
line weight increased the risk of macrosomia and maternal
hypertension.
Our findings on baseline weight and outcomes were consis-
tent with prior studies in the general population, including
studies across resource settings, and studies that defined
baseline weight before or during pregnancy [23,25,30-34].
Several prior studies, primarily from the United States (US)
Table 5. Sensitivity analysis of baseline maternal weight (<24 weeks) and outcomes, stratified by CD4 count
Baseline weight (kg)
<50 50 to 60 60 to 70 70 to 80 80 to 90 >90
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Any severe adverse outcome
CD4 < 500 40 (17.8%) 64 (13.3%) 63 (13.1%) 24 (8.7%) 12 (5.6%) 11 (5.1%)
aRR (95% CI) 1.46 (1.01, 2.11) 1.01 (0.72, 1.42) REF 0.64 (0.41, 1.01) 0.62 (0.35, 1.13) 0.85 (0.47, 1.56)
CD4 > 500 51 (15.7%) 84 (12.3%) 79 (13.4%) 50 (11.6%) 26 (10.4%) 22 (9.5%)
aRR (95% CI) 1.31 (0.93, 1.83) 1.00 (0.74, 1.34) REF 0.84 (0.60, 1.18) 0.79 (0.52, 1.20) 0.69 (0.44, 1.09)
Very preterm delivery
CD4 < 500 12 (5.3%) 23 (4.8%) 15 (3.1%) 5 (1.8%) 1 (0.67%) 1 (1.0%)
aRR (95% CI) 1.9 (0.9, 4.1) 1.7 (0.9, 3.2) REF 0.61 (0.22, 1.7) 0.23 (0.03, 1.72) 0.34 (0.05, 2.57)
CD4 > 500 7 (2.2%) 17 (2.5%) 27 (4.6%) 13 (3.0%) 4 (1.59%) 4 (1.72%)
aRR (95% CI) 0.54 (0.23, 1.24) 0.57 (0.32, 1.05) REF 0.62 (0.32, 1.19) 0.32 (0.11, 0.91) 0.26 (0.08, 0.86)
Very small for gestational age
CD4 < 500 28 (12.5%) 39 (8.2%) 43 (9.0%) 15 (5.5%) 8 (5.4%) 6 (6.3%)
aRR (95% CI) 1.51 (0.95, 2.39) 0.88 (0.57, 1.36) REF 0.62 (0.35, 1.11) 0.62 (0.29, 1.29) 0.69 (0.30, 1.59)
CD4 > 500 42 (13.0%) 63 (9.3%) 45 (7.7%) 29 (6.8%) 16 (6.4%) 14 (6.1%)
aRR (95% CI) 1.81 (1.19, 2.75) 1.29 (0.89, 1.89) REF 0.86 (0.54, 1.37) 0.86 (0.49, 1.51) 0.84 (0.47, 1.50)
Perinatal death
CD4 < 500 10 (4.4%) 17 (3.5%) 21 (4.4%) 12 (4.4%) 4 (2.7%) 6 (6.3%)
aRR (95% CI) 1.16 (0.55, 2.46) 0.89 (0.47, 1.69) REF 0.92 (0.45, 1.90) 0.63 (0.22, 1.82) 1.40 (0.58, 3.41)
CD4 > 500 10 (3.1%) 17 (2.5%) 26 (4.4%) 18 (4.2%) 8 (3.2%) 8 (3.5%)
aRR (95% CI) 0.91 (0.44, 1.90) 0.66 (0.36, 1.22) REF 0.90 (0.49, 1.66) 0.71 (0.32, 1.57) 0.68 (0.30, 1.57)
Macrosomia
CD4 < 500 0 (0%) 5 (1.0%) 6 (1.3%) 8 (2.9%) 5 (3.4%) 7 (7.3%)
aRR (95% CI) 0 0.80 (0.24, 2.62) REF 2.37 (0.83, 6.77) 2.74 (0.85, 8.88) 5.93 (2.02, 17.43)
CD4 > 500 0 (0%) 9 (1.3%) 10 (1.7%) 12 (2.8%) 11 (4.4%) 9 (3.9%)
aRR (95% CI) 0 0.77 (0.32, 1.90) REF 1.62 (0.70, 3.71) 2.49 (1.07, 5.81) 1.99 (0.795.00)
Maternal hypertension
CD4 < 500 26 (11.6%) 66 (13.7%) 88 (18.4%) 66 (24.0%) 49 (32.9%) 32 (33.7%)
aRR (95% CI) 0.69 (0.46, 1.05) 0.81 (0.60, 1.08) REF 1.21 (0.91, 1.61) 1.66 (1.23, 2.23) 1.69 (1.21, 2.37)
CD4 > 500 30 (9.2%) 86 (12.6%) 109 (18.5%) 97 (22.6%) 74 (29.5%) 81 (35.1%)
aRR (95% CI) 0.49 (0.33, 0.74) 0.72 (0.55, 0.93) REF 1.19 (0.93, 1.52) 1.56 (1.20, 2.01) 1.78 (1.39, 2.29)
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and Europe, found a V-shaped or U-shaped relationship
between preterm delivery and baseline maternal weight, while
we found the risk of very preterm delivery decreased steadily
with increasing baseline weight category [30,34,35]. This may
be due to differences in study populations, as Botswana has
less morbid obesity than the United States/Europe [36,37]
and we may have had decreased power to detect risk in the
highest weight category. In addition, obesity has been specifi-
cally associated with indicated preterm delivery [38,39], and
obstetric practices may differ in Botswana such that fewer
indicated preterm deliveries typically occur. The aetiology of
preterm delivery may also differ in Botswana, and among
WLWHIV who are on ART [10,40].
Our study is also consistent with the results from the
VESTED study [21], which is the only randomized study of a
TAF/FTC/DTG regimen in pregnancy. VESTED demonstrated
both higher GWG and decreased adverse birth outcomes in
women randomized to TAF/FTC/DTG compared to TDF/FTC/
EFV, including fewer SGA and preterm deliveries. It is note-
worthy that our study also identified effect modification by
ART regimen (DTG vs. EFV) in the relationship between
baseline weight and hypertension, though this is of unclear
significance and did not result in increased severe adverse
birth outcomes with DTG. Further research is needed to
understand outcome differences with additional antiretroviral
combinations, and the mechanism of TAF- and DTG-
associated weight gain, to determine if weight-based decisions
are warranted for choosing specific ART combinations to
improve pregnancy outcomes and maternal health.
A strength of our study was the large sample size with the
power to evaluate multiple outcomes, including individual sev-
ere adverse birth outcomes, which have the most clinical
impact. Interestingly, our data show no relationship between
baseline weight and perinatal death. This may be because the
increased risk of perinatal death among infants born very pre-
term or very SGA in low weight women was balanced by the
increased risk of perinatal death with macrosomia and hyper-
tension in high weight women. However, our results should
not be interpreted as equivalency of low baseline weight with
high baseline weight, as we were unable to measure many
outcomes associated with weight, including gestational dia-
betes, post-partum haemorrhage, infection, neonatal growth
Figure 3. Risk of outcomes by second trimester weight gain in pregnancy (12  2 weeks to 24  2 week GA) among women on ART at
conception.
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and neurodevelopment. Rather, our findings can be used to
support the importance of maternal health interventions that
focus on both extremes of maternal weight, particularly in
high HIV-prevalence, low resource settings, where there are
currently dual epidemics of malnutrition and obesity [41].
One major limitation of our study is that we were unable to
calculate BMI. Our findings may overestimate risks among
women at the extremes of height and we cannot use our find-
ings to make clinical recommendations for weight and weight
gain at the individual level. While BMI is a more accurate pre-
dictor of birth outcomes than weight, it is unlikely to signifi-
cantly change the interpretation of our results, as few women
in the highest and lowest baseline weight categories will have
a normal BMI. For example only women taller than 198.6 cm
(6 feet 2.7 inches) will have a BMI < 25 with weight >90 kg,
and only women shorter than 158 cm (5 feet 2 inches) have
BMI > 20 with weight <50 kg. Similarly, defining baseline
weight at <24 weeks’ gestation (available for 70% of women
in our cohort), rather than first-trimester (available for 31%)
or pre-pregnancy weight (available for 33%) may underesti-
mate risk in the low weight categories and overestimate risk
in the higher weight categories. However, our sensitivity anal-
ysis using baseline weight measured at <14 weeks’ GA, and
reported pre-pregnancy weight, showed that these differences
were small and did not change the interpretation of results.
This supports prior World Health Organization (WHO) recom-
mendations to use weight at the first antenatal clinic visit to
identify high-risk pregnancies [34], particularly in limited
resource settings, where pre-pregnancy BMI is not routinely
known.
Other limitations in our study included inadequate ability to
evaluate the impact of CD4 count due to missingness; inability
to account for repeat pregnancies during the study period;
scales used in routine care that may not be properly calibrated;
and absence of early prenatal ultrasound for GA dating. How-
ever, none of these limitations were likely to differ by weight
strata. Additionally, our analysis evaluated weight gain in the
second trimester, and we cannot make inferences about the
effect of weight gain in the third trimester on later pregnancy
outcomes. A relatively small proportion of the cohort had sec-
ond trimester weight gain measured because most women do
not present to antenatal care early enough to be included in
this analysis, so our results may not be generalizable. Finally,
blood pressure may be overestimated in obese patients if an
inappropriately small cuff is used and could overestimate hyper-
tension among women of high baseline weight in our study.
Our study results help to frame the discourse on HIV treat-
ment optimization in women. Most of the ART-weight gain lit-
erature has focused on risks that will increase from excess
weight gain and obesity [9,42]. However, our findings suggest
there may also be benefits from weight gain if newer ART reg-
imens lead to fewer women with low baseline weight and low
weight gain in pregnancy. The balance of risks and benefits will
likely vary by setting.
5 | CONCLUSIONS
Among women on ART at conception, low baseline weight in
pregnancy was associated with increased risk of severe birth
Table 6. Second trimester weight gain (kg/week) between 12  2 and 24  2 weeks’ gestational age and outcomes, with and with-
out adjusting for baseline weight (BLW)
Second trimester weight gain (kg/week)
<0.15 0.15 to 0.25 0.25 to 0.35 0.35 to 0.45 0.45 to 0.55 >0.55
Any severe adverse
outcome (N, %)
113 (12.4%) 88 (13.1%) 100 (12.1%) 99 (12.8%) 71 (11.8%) 78 (11.9%)
aRR w/o BLW (95% CI) 1.02 (0.79, 1.32) 1.09 (0.83, 1.43) REF 1.05 (0.81, 1.37) 1.02 (0.76, 1.35) 0.98 (0.74, 1.31)
aRR w/BLW (95% CI) 1.11 (0.86, 1.44) 1.14 (0.87, 1.50) REF 1.04 (0.79, 1.34) 0.98 (0.74, 1.31) 0.99 (0.74, 1.31)
Very preterm delivery (N, %) 22 (2.4%) 22 (3.3%) 26 (3.1%) 25 (3.2%) 21 (3.5%) 28 (4.3%)
aRR w/o BLW (95% CI) 0.72 (0.41, 1.23) 1.03 (0.59, 1.80) REF 0.95 (0.55, 1.66) 1.12 (0.63, 1.97) 1.28 (0.75, 2.20)
aRR w/BLW (95% CI) 0.76 (0.43, 1.36) 1.06 (0.61, 1.86) REF 0.94 (0.54, 1.64) 1.09 (0.62, 1.93) 1.29 (0.75, 2.20)
Very small for gestational
age (N, %)
86 (9.5%) 58 (8.7%) 65 (7.9%) 64 (8.3%) 49 (8.2%) 47 (7.2%)
aRR w/o BLW (95% CI) 1.23 (0.90, 1.68) 1.11 (0.79, 1.58) REF 1.09 (0.78, 1.52) 1.09 (0.76, 1.56) 0.91 (0.62, 1.32)
aRR w/BLW (95% CI) 1.37 (0.997, 1.80) 1.19 (0.84, 1.68) REF 1.07 (0.77, 1.50) 1.06 (0.74, 1.51) 0.92 (0.63, 1.33)
Perinatal death (N, %) 26 (2.9%) 30 (4.5%) 27 (3.3%) 26 (3.4%) 25 (4.1%) 31 (4.7%)
aRR w/o BLW (95% CI) 0.80 (0.47, 1.38) 1.32 (0.79, 2.20) REF 1.00 (0.59, 1.71) 1.29 (0.76, 2.20) 1.39 (0.83, 2.32)
aRR w/BLW (95% CI) 0.82 (0.48, 1.42) 1.33 (0.75, 2.23) REF 1.00 (0.58, 1.70) 1.28 (0.75, 2.18) 1.39 (0.83, 2.24)
Macrosomia (N, %) 16 (1.8%) 14 (2.1%) 16 (1.9%) 18 (2.3%) 10 (1.7%) 27 (4.1%)
aRR w/o BLW (95% CI) 0.91 (0.46, 1.81) 1.07 (0.52, 2.17) REF 1.22 (0.63, 2.38) 0.78 (0.35, 1.75) 2.01 (1.08, 3.74)
aRR w/BLW (95% CI) 0.80 (0.40, 1.59) 0.99 (0.49, 2.02) REF 1.25 (0.64, 2.43) 0.81 (0.36, 1.81) 1.94 (1.04, 3.60)
Maternal hypertension (N, %) 201 (22.2%) 153 (22.8%) 170 (20.5%) 149 (19.3%) 126 (20.9%) 149 (22.7%)
aRR w/o BLW (95% CI) 1.02 (0.85, 1.22) 1.09 (0.90, 1.32) REF 0.92 (0.75, 1.12) 1.03 (0.84, 1.27) 1.11 (0.91, 1.35)
aRR w/BLW (95% CI) 0.96 (0.80, 1.15) 1.04 (0.86, 1.26) REF 0.93 (0.76, 1.13) 1.06 (0.86, 1.29) 1.10 (0.91, 1.34)
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Figure 4. Heatmaps of baseline weight (between 10 and 14 weeks GA) and outcomes (any severe adverse outcome, macrosomia and mater-
nal hypertension), stratified by second trimester weight gain (between 12  2 and 24  2 weeks GA), for (A) severe birth outcomes, (B)
macrosomia, (C) maternal hypertension.Each cell represents the number of outcomes and the percentage of outcomes among women in that indi-
vidual cell.
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outcomes while high baseline weight was associated with
increased risk of macrosomia and maternal hypertension.
ART-associated weight gain with newer antiretroviral medica-
tions may have both positive and negative benefits for mater-
nal and child health depending on the mother’s weight
entering pregnancy. Further research is needed to understand
how newer ART combinations differentially impact outcomes
among high- and low-weight women.
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